| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_54ff7496ce3a11d34a6bb313ee741d16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_baa955465a00feb73e4e6d54a1567aed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fe171d48440697e4545200ac11d5a9bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d95d3a84b2b853ce7248fcb00d0ac91e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2009-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f2a7d70a728f9bf7c50b91b952f7969
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_115202bc8d3da35e0d57afa727034bf3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58b27cc714a2b2427d9df3d4880d2ef9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6998eb267bd539f3de7d2733288c443 |
| publicationDate |
2011-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011262453-A1 |
| titleOfInvention |
Markers for Assessing the Susceptibility of Cancer to IGF-1R Treatment |
| abstract |
The present invention relates to a method of predicting response of a cancer cell tissue to IGF-IR treatment. The inventors have observed a direct relationship between the expression of survivin, ErbB 3 and E-cadherin and the response of cancer cells to IGF-IR treatment. This observation permits screening of tumor cells prior to treatment to determine whether the cancer will respond to IGF-IR treatment, and/or to monitor the efficacy of such a treatment by conducting “before and after” assessments of the expression of these markers |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012106556-A2 |
| priorityDate |
2008-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |